Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AADI - Aadi Bioscience, Inc.

IEX Last Trade
3.01
0   0%

Share volume: 0
Last Updated: Thu 26 Dec 2024 02:30:35 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 22.93%

PREVIOUS CLOSE
CHG
CHG%
$3.01
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-11.50%
1 Month
35.14%
3 Months
57.89%
6 Months
76.47%
1 Year
52.28%
2 Year
-76.04%
Key data
Stock price
$3.01
P/E Ratio 
0.00
DAY RANGE
$1.87 - $2.75
EPS 
$0.00
52 WEEK RANGE
$1.41 - $3.60
52 WEEK CHANGE
$44.23
MARKET CAP 
44.553 M
YIELD 
N/A
SHARES OUTSTANDING 
24.615 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
1.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,754,244
AVERAGE 30 VOLUME 
$661,855
Company detail
CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.

Recent news